The Unrealized Potential of Cascade Testing

• by Miguel Barajas, Lainie Friedman Ross

• June 30, 2026

Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer

• by Yi Chen, Xiaofeng Chen, Bowen Yue, Xinwei Zhong, Hao Zhang, Xiaohong Chen, Xiangguang Chen, Zhuozhi Dai, Zhiqi Yang

• June 18, 2026

Metaplastic breast carcinoma with osteosarcomatous differentiation: a case report

• by Xiang Zhao, XiaoYu Sun, Jiaqi Liu

• June 30, 2026

ESMO Breast Cancer 2026 Highlights: Saci-IO HR+

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.

• June 26, 2026

• 1 min